FSD Pharma CEO Lays Out Roadmap in Exclusive Interview with CFN Media


Ryan Allway

May 10th, 2019

App, Exclusive, News, Top Story


FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) is a licensed producer focused on building out a 3.9 million sq. ft. indoor hydroponic facility near Toronto capable of producing 400,000 kilograms of dried cannabis per year. With a newly acquired sales license and 25,000 sq. ft. already in production, the company is on the cusp of generating revenue through partnerships with its tenants where it’s entitled to royalty income on production.

CFN Media recently caught up with Chairman and CEO Dr. Raza Bokhari at the Arcview Investor Forum in Vancouver to discuss the company and its plans for 2019.

 

Licenses & Acquisitions

FSD Pharma recently appointed Dr. Sara May as President of FV Pharma Inc., the company’s licensed producer subsidiary. Dr. May is an experienced geneticist that brings a decade of experience designing, implementing, and managing large-scale research projects into the fold. Under her guidance, the company secured a much anticipated sales license for plants and seeds in April, which opens the door to near-term commercialization.

The company has also been active in expanding distribution channels for its medical cannabis products. In April, the company announced a share exchange with Aura Health Inc., an international network of vertically-integrated cannabis assets with a major presence in Europe. Management’s goal with the transaction is to expand its distribution footprint into Europe—a region that’s expected to see significant demand growth.

The company also recently announced the acquisition of Prismic Pharmaceuticals, a U.S.-based specialty pharmaceutical company led by a former founder of Shire plc, which was recently acquired for $60 billion. The acquisition fits within the company’s long-term ambitions to develop synthetic cannabinoids that could be approved by the U.S. FDA for the treatment of CNS disorders, pain management, and other indications.

Short- & Long-term Goals

FSD Pharma’s approach to the cannabis market differs from many other licensed producers. Rather than simply producing cannabis flower and oil, the company has focused on identifying ways to bring medicinal benefits to patients. Its indoor hydroponic facility is designed to ensure maximum quality, while partnerships with Canntab Therapeutics and Pharmastrip Corp. incorporate innovative new delivery methods.

Over the long-term, the company hopes to develop synthetic cannabinoid technologies that could translate to more predictable medicine, lower costs, and better patient outcomes. The company’s acquisition of Prismic Pharmaceuticals and letter of intent with Solarvest represents a step in this direction. Solarvest’s algae-based synthetic cannabinoid research could dramatically shorten the production time for specific cannabinoid molecules.

Dr. Bokhari mentions that the company also plans to list their stock on the New York Stock Exchange (NYSE), which could improve liquidity for existing shareholders and open the door to greater investment.

Looking Ahead

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) has been making tremendous strides over the past few months after securing a sales license and making a number of strategic partnerships and acquisitions. Investors may want to keep an eye on the company as FSD continues to move closer to a commercial stage for medical cannabis production while simultaneously developing its pharmaceutical products.

For more information, visit the company’s website at www.fsdpharma.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading